The Future of Anti-Amyloid Trials
P S Aisen1, J Cummings, R Doody
1P.S. Aisen, University of Southern California Alzheimer's Therapeutic Research Institute, San Diego, CA, USA, paisen@usc.edu.
The Journal of Prevention of Alzheimer'S Disease
|May 29, 2020
Summary
Recent Alzheimer's disease (AD) trial terminations were impactful, but positive signals for amyloid-targeting therapies are encouraging. Future AD drug development requires better biomarker understanding and early intervention strategies.
Area of Science:
- Neuroscience
- Pharmacology
- Clinical Research
Background:
- Alzheimer's disease (AD) drug development faces challenges, with numerous clinical trial terminations for amyloid-targeting therapies.
- Despite setbacks, recent positive findings have renewed interest in the amyloid hypothesis and related treatment strategies.
Purpose of the Study:
- To convene the EU-US Clinical Trials on Alzheimer's Disease (CTAD) Task Force to discuss learnings from recent AD trials.
- To identify critical factors for improving future Alzheimer's disease clinical trials and treatment development.
Main Methods:
- Discussion and knowledge sharing among experts at the CTAD Task Force meeting.
- Review of data from anti-amyloid monoclonal antibody therapies in Alzheimer's disease clinical trials.
Main Results:
- Key factors for successful trials include understanding specific amyloid targets, antibody mechanisms, comprehensive biomarkers, and optimal dosing.
- Amyloid-Related Imaging Abnormalities - effusion type (ARIA-E) are manageable, and interim analyses should be approached with caution.
Conclusions:
- Future Alzheimer's disease treatment development opportunities lie in novel biomarkers, early disease intervention, and combination therapies.
- Continued research and strategic trial design are crucial for advancing effective Alzheimer's disease therapies.
Keywords:
Alzheimer’s diseaseBACE inhibitorsamyloid hypothesiscombination therapydementiamonoclonal antibody treatmentMore Related Videos
Related Concept Videos
01:22Alzheimer's Disease: Treatment
680
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
680
03:03Amyloid Fibrils
11.4K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
11.4K
03:03Amyloid Fibrils
6.2K
6.2K
01:26Alzheimer's Disease: Overview
1.5K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K
01:26Atherosclerosis III: Management
259
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
259